Amneal Pharmaceuticals Inc (Amneal)(Nasdaq: AMRX), an integrated pharmaceutical company, announced on Friday the appointment of David A. Buchen to the newly expanded role of senior vice president, chief legal officer and corporate secretary.
In his new role, Buchen will report to president and CEO Robert Stewart. Buchen will be responsible for leading Amneal's global legal, Intellectual Property (IP) and corporate compliance functions, as well as aligning the company's corporate legal strategies to drive Amneal's continued growth.
Also, to ensure a smooth leadership transition, Amneal's senior vice president, general counsel, Sheldon Hirt, will remain on board through January 2019 before leaving the company to pursue other opportunities.
Most recently, Buchen served as a consultant to the pharmaceutical industry, providing counsel to various global and US manufacturing, marketing and distribution companies. Prior to establishing his consultancy, he held several executive leadership roles, including serving as EVP – Commercial, North American Generics and International, as well as 12 years as chief legal officer and corporate secretary at Watson Pharmaceuticals (rebranded as Actavis plc).
Amneal Pharmaceuticals is focused on developing, manufacturing and distributing generic, brand and biosimilar products.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling